You are here: Industry Insights > BioNTech

News List

US fast tracks Pfizer/BioNTech coronavirus vaccines pharmatimes
July 17, 2020
US regulators have fast-tracked Pfizer and BioNTech's novel coronavirus vaccine candidates BNT162b1 and BNT162b2.
FDA grants fast track status to Pfizer and BioNTech Covid-19 vaccines pharmaceutical-technology
July 15, 2020
Pfizer and BioNTech have received fast track designation from the US Food and Drug Administration (FDA) for two of their four potential Covid-19 vaccines.
Pfizer, BioNTech’s coronavirus vaccine candidates get US FDA’s ‘fast track’ status expresspharma
July 14, 2020
The market is “desperate to latch onto any positive developments in the vaccine field,” JP Morgan analyst Cory Kasimov said in a note.
Pfizer, BioNTech’s COVID-19 vaccine expected to be ready for approval by year end expresspharma
July 13, 2020
The experimental vaccine, which showed promise against the fast-spreading respiratory illness in early stage human testing, is expected to move into a large trial involving 30,000 healthy participants later this month.
Pfizer, BioNTech post positive data from study of COVID-19 vaccine candidate expresspharma
July 02, 2020
If studies are successful and mRNA-based vaccine candidate receives regulatory approval, companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.
EIB Provides BioNTech with Debt Financing for COVID-19 Vaccine Development, Manufacturing americanpharmaceuticalreview
June 23, 2020
The European Investment Bank (EIB) and BioNTech SE concluded a €100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine program.
BioNTech to receive up to €100m from EIB for vaccine development pharmaceutical-technology
June 15, 2020
German immunotherapy company BioNTech has signed a €100m debt financing agreement with the European Investment Bank (EIB) for the development of its Covid-19 vaccine candidate, BNT162.
Pfizer, BioNTech dose first participants in Covid-19 vaccine trial in US pharmaceutical-business-review
May 08, 2020
Pfizer and Biopharmaceutical New Technologies (BioNTech) have dosed the first participants of a phase 1/2 trial for their Covid-19 vaccine candidate BNT162 in the US.
First Patient Dosed With Pfizer’s Potential COVID-19 Vaccine in US europeanpharmaceuticalreview
May 07, 2020
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
Germany to begin first clinical trial of COVID-19 vaccine candidate europeanpharmaceuticalreview
April 24, 2020
A Phase I/II clinical trial for BioNTech’s BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page